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Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) signifi-
cantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previ-
ously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship
of incident anemia with triple therapy. A total of 1,097 patients received a 4-week lead-in
of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC
plus PegIFN/RBV using response-guided therapy (BOC/RGT); and (3) BOC plus PegIFN/
RBV for 44 weeks (BOC/PR48). The management of anemia (hemoglobin [Hb] <10 g/
dL) included RBV dose reduction and/or erythropoietin (EPO) use. A total of 1,080
patients had 1 Hb measurement during treatment. The incidence of anemia was 50% in
the BOC arms combined (363/726) and 31% in the PR48 arm (108/354, P < 0.001).
Among BOC recipients, lower baseline Hb and creatinine clearance were associated with
incident anemia. In the BOC-containing arms, anemia was managed by the site investiga-
tors as follows: EPO without RBV dose reduction, 38%; RBV dose reduction without
EPO, 8%; EPO with RBV dose reduction, 40%; and neither RBV dose reduction nor
EPO, 14%. SVR rates were not significantly affected by management strategy (70%-74%),
and overall patients with anemia had higher rates of SVR than those who did not develop
anemia (58%). Serious and life-threatening adverse events (AEs) and discontinuations due
to AEs among BOC-treated patients did not differ by EPO use. Conclusion: With BOC/
PR therapy, SVR rates in patients with incident anemia were higher than nonanemic
patients and did not vary significantly according to the investigator-selected approach
for anemia management. Prospective studies are needed to confirm this observation.
(HEPATOLOGY 2013;57:974-984)
C
hronic hepatitis C virus (HCV) infects more
than 170 million people worldwide, is a lead-
ing cause of cirrhosis, end-stage liver disease,
and hepatocellular carcinoma, and is the most common
indication for liver transplantation in Europe and the
United States.1 Since 2001, peginterferon alfa-2b
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(PegIFN) in combination with ribavirin (RBV) has been
the standard treatment for HCV, leading to sustained
virologic response (SVR) in approximately 40% of per-
sons infected with HCV genotype-1.2-5 However, as a
result of RBV dose-dependent hemolytic anemia and
PegIFN-induced suppression of hematopoiesis, this regi-
men causes significant reductions in hemoglobin (Hb)
level in most treated patients, resulting in anemia,
defined as an Hb level <10 g/dL, in approximately 30%
of patients.6-8 Interestingly, the development of PegIFN/
RBV-related anemia has been strongly associated with
greater likelihood of SVR.9 In a large study involving
3,070 previously untreated HCV genotype 1 infected
patients, patients who developed anemia had significantly
higher rates of SVR (48.8%) compared with nonanemic
patients (36.7%); in this analysis, RBV dose reduction to
manage the anemia in these patients was not associated
with a decrease in SVR, suggesting that anemia may be a
pharmacodynamic marker of RBV exposure.10 In addi-
tion, the effect of erythropoiesis-stimulating agents
(ESAs), used for the management of PegIFN/RBV-
related anemia,10-13 varied by time to anemia; patients
with early-onset anemia (8 weeks of treatment) had
higher rates of SVR with ESA use, whereas no effect was
observed in those with late-onset anemia.10
More recently, phase 2 and 3 studies have shown that
the addition of boceprevir (BOC), an HCV NS3/4A
protease inhibitor (PI), to PegIFN/RBV therapy
resulted in both significantly higher rates of SVR and of
incident anemia compared with PegIFN-RBV alone.14-
17 In these clinical trials, the management of anemia
included RBV dose reduction and, at the discretion of
the investigator, the use of erythropoietin (EPO). The
relationship of incident anemia with triple therapy, the
approach used for its management and clinical out-
comes such as virologic response and safety has not
been evaluated. The primary objective of this analysis
was to determine the relationship between virologic
response, adverse events (AEs) and treatment-associated
anemia and its management, in previously untreated
HCV genotype 1-infected patients enrolled in The Ser-
ine Protease Inhibitor Therapy 2 (SPRINT-2) Trial.15
Patients and Methods
Study Design. The SPRINT-2 Trial was a phase 3,
international, randomized, placebo-controlled study
comparing the safety and efficacy of therapy with
PegIFN and RBV (PegIntron and Rebetol, respectively;
Merck) to two treatment regimens that added BOC
(Victrelis, Merck) after a lead-in treatment period with
PegIFN/RBV alone. Enrolled patients were randomized
in a 1:1:1 ratio to one of three treatment groups after
stratification by baseline HCV RNA viral load
(400,000 versus >400,000 IU/mL) and HCV geno-
type 1 subtype (1a versus 1b).
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Patients. Previously untreated patients 18 years of
age weighing 40-125 kg with chronic HCV genotype
1 and plasma HCV RNA level 10,000 IU/mL were
eligible. Exclusion criteria included liver disease of
other etiology; decompensated cirrhosis; renal insuffi-
ciency; human immunodeficiency virus or hepatitis B;
pregnant/breastfeeding women; or active malignancy.
Pretreatment liver biopsies were assigned METAVIR
fibrosis and steatosis scores by a single pathologist who
was unaware of the assignment to BOC or placebo.
Study Regimens. PegIFN was administered subcuta-
neously at 1.5 lg/kg once weekly; RBV was dosed accord-
ing to body weight at 600-1,400 mg/day (divided twice
daily dose). BOC was administered orally at a dose of 800
mg three times daily (to be taken with food and with an
interval of 7-9 hours between doses) in four capsules of
200 mg each. Placebo was matched to BOC. The study
was double-blinded regarding the administration of BOC.
A total of 1,097 patients were randomized and
treated. All patients received PegIFN/RBV during the
4-week lead-in period (Supporting Fig. 1). Patients
randomized to control received PegIFN/RBV treat-
ment for 44 weeks after the lead-in period, as well as
placebo three times daily beginning at week 5 (PR48).
Patients randomized to the response-guided therapy
(RGT) regimen received PegIFN/RBV plus BOC for a
total of 24 weeks after the lead-in period. If HCV
RNA levels were undetectable from week 8 through
week 24, treatment was considered complete; however,
if HCV RNA levels were detectable at any visit from
week 8 up to but not including week 24, PegIFN/
RBV was continued, and placebo was administered at
week 28 through week 48 (abbreviated at BOC/RGT).
Patients randomized to the third regimen received
PegIFN/RBV plus oral BOC for 44 weeks after the
lead-in period (abbreviated as BOC/PR48). In all
groups, patients with detectable HCV RNA at week
24 were discontinued for virologic futility.
Management of Anemia. The management of ane-
mia was identical for all three arms. RBV dose reduction
(in 200 mg increments) was recommended when the
Hb level was <10 g/dL and RBV dose interruption or
discontinuation was recommended when the Hb level
was <8.5 g/dL. At the discretion of the study
investigator, RBV could be increased to full dose directly
or in steps, respectively, when the AE subsided. The use
of EPO was at the discretion of the investigator.
The sponsor provided EPO to patients as well
as guidelines for its use in the study protocol, which
is available at http://www.nejm.org/doi/suppl/10.1056/
NEJMoa1010494/suppl_file/nejmoa1010494_appendix.
pdf.18,19 The recommended initial EPO dose was 40,000
U subcutaneously once weekly. EPO was not to be admin-
istered when Hb was 12 g/dL. EPO was to be reduced
by 25%-50% for Hb increases of >1 g/dL within 2
weeks, or for Hb increases >2 g/dL within 4 weeks.
Statistics. The trial was designed as a superiority
study to detect differences in SVR rates between either
of the two BOC regimens (BOC/RGT or BOC/PR48)
and standard therapy (PR48). The data analysis plan
is available at http://www.nejm.org/doi/suppl/10.1056/
NEJMoa1010494/suppl_file/nejmoa1010494_appendix.
pdf. The primary analyses used all patients who had
received 1 dose of any study medication.
The efficacy analyses presented here are based on all
patients who underwent an Hb measurement at base-
line and at least once during the treatment phase and
up to 7 days after treatment end date. Plasma HCV
RNA levels were measured using the TaqMan 2.0
assay (Roche Diagnostics), which has lower limits of
quantification and detection of 25 and 9.3 IU/mL,
respectively; the lower limit of detection was used for
decision making at various points throughout the
study and for analysis of SVR.
As the proportion of patients who became anemic
during treatment and the proportion of patients
who used EPO during treatment were similar in the
BOC/RGT (49% [179/368] and 43% [159/368]) and
BOC/PR48 arms (50% [184/366] and 43% [159/
366]) these treatment groups were combined for subse-
quent analysis (abbreviated as BOC/PR). SVR by
anemia status (yes, no) and by anemia management
strategy (EPO use only, RBV dose reduction only,
both, or neither) was also summarized. The proportion
of patients who achieved SVR, relapse, or undetectable
HCV-RNA at various time points by EPO use and
anemia management strategy were also summarized for
patients who received BOC/PR.
Hb decline during treatment and follow-up was sum-
marized for five groups: (1) all patients; (2) patients
randomized to the PR48 arm; (3) patients randomized
to the BOC/RGT arm who were early responders (unde-
tectable HCV RNA at week 8); (4) patients randomized
to the BOC/RGTarm who were late responders (detecta-
ble HCV RNA at week 8 but undetectable by week 24);
and (5) patients randomized to the BOC/PR48 arm.
Safety data are summarized separately for the BOC/
RGT and BOC/PR48 arms by EPO use.
Results
Patient Characteristics. The study randomized and
treated 1,097 patients, 1,080 of whom had at least
one Hb measurement during the treatment phase and
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up to 7 days after treatment end date (PR48, 354
patients; BOC/PR, 726 patients). Overall, the inci-
dence of anemia (Hb <10 g/dL) was 50% in the
BOC/PR arms (363/726) and 31% in the PR48 arm
(108/354) (P < 0.001). Severe anemia (Hb <8.5 g/
dL) was less common, occurring in 4% (14/354) and
7% (52/726) of patients in the PR48 and BOC/PR
arms, respectively (P ¼ 0.04) (Fig. 1).
Among patients who developed anemia, the maxi-
mum mean Hb decline was 4.8 g/dL (SD 1.3) and
5.3 g/dL (SD 1.4) in the PR48 and BOC/PR arms,
respectively. After the addition of BOC or placebo, the
mean maximum Hb decline between weeks 4 and 8
was 1.3 g/dL among patients treated with BOC and
0.6 g/dL among those treated with placebo. After 4
weeks of therapy with PR, the change in Hb level
from baseline was predictive of subsequent anemia
after the addition of BOC; however, the negative post-
test probability for the development of anemia with an
observed Hb decline 2 g/dL was relatively high
(28.5%-37.2%). The negative predictive value of the
magnitude of hemoglobin declined after 2 weeks of
BOC/PR (treatment week 6) and subsequent anemia
was similar (Supporting Tables 1 and 2). After discon-
tinuation of therapy at 28 weeks for patients in the
RGT arm who met criteria for early discontinuation or
at 48 weeks for all other patients, Hb returned to pre-
treatment levels; no difference in the magnitude or
rate of return was detected in the PR48 and BOC/
PR48 arms (Fig. 2).
Baseline demographics and clinical characteristics of
patients with and without incident anemia who
received BOC/PR are shown in Table 1. Anemia
occurred more frequently in women (65%) and
patients >40 years old (53%) compared with men
(41%) and patients <40 years old (33%). In addition,
patients who became anemic during BOC/PR
treatment had significantly lower baseline Hb levels
(Supporting Fig. 2), had lower estimated creatinine
clearance, and were more likely to be taking statins.
Multivariate analysis included the following baseline
factors as predictors of incident anemia among patients
who received BOC; statin use, baseline Hb level
Fig. 1. Hemoglobin levels.
Fig. 2. Mean hemoglobin concentration over time by treatment
arm. The x axis numbers are not to scale.
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(continuous variable), estimated baseline creatinine
clearance (continuous variable), and sex. Only lower
baseline Hb level was predictive of incident anemia
(odds ratio, 0.58; 95% confidence interval, 0.51-0.67;
P < 0.0001) whereas lower baseline creatinine clear-
ance was borderline significant (odds ratio, 0.9955;
P ¼ 0.0524).
Anemia, Hb Decline, and Virologic Response. For
patients treated with BOC/PR, the magnitude of Hb
decline during therapy and the development of anemia
were associated with virologic response. Among
patients treated with BOC/PR who did not develop
anemia, HCV RNA was undetectable at the end of
treatment (EOT) in 67% (245/363), whereas among
patients who developed anemia, EOT virologic
response was observed in 81% (293/363) (Table 2).
Similarly, the observed SVR rate was higher in patients
with incident anemia during treatment with BOC/PR
Table 1. Characteristics According to Treatment-Related Anemia
Characteristics
BOC Arms Combined (n ¼ 726)
PHb 10 g/dL (n ¼ 363) Hb <10 g/dL (n ¼ 363)
Sex, n/m (%)
Female 99/280 (35) 181/280 (65) <0.0001
Male 264/446 (59) 182/446 (41) <0.0001
Race, n/m (%)
White 310/593 (52) 283/593 (48) 0.12
Black/African American 40/105 (38) 65/105 (62) 0.001
Other 13/28 (46) 15/28 (54) 0.60
Age
40 years, n/m (%) 73/109 (67) 36/109 (33) <0.0001
>40 years, n/m (%) 290/617 (47) 327/617 (53) 0.04
Baseline weight, kg, mean (SD) 82.2 (16.8) 81.7 (17.6) 0.68
Baseline HCV subtype,* n/m (%)
1a 241/464 (52) 223/464 (48) 0.24
1b 113/240 (47) 127/240 (53) 0.20
Missing data 9/22 (41) 13/22 (59) 0.23
Baseline HCV-RNA viral load, n/m (%)
2,000,000 IU/mL 105/229 (46) 124/229 (54) 0.08
>2,000,000 IU/mL 258/497 (52) 239/497 (48) 0.23
Baseline statin use, n/m (%) 5/16 (31) 11/16 (69) 0.04
Baseline METAVIR fibrosis score, n/m (%)
F0/F1/F2 317/625 (51) 308/625 (49) 0.61
F3/F4 32/75 (43) 43/75 (57) 0.07
Missing 14/26 (54) 12/26 (46) 0.58
Baseline steatosis, n/m (%)
Absence 108/212 (51) 104/212 (49) 0.70
Presence 255/514 (50) 259/514 (50) 0.80
Missing 14/26 (54) 12/26 (46) 0.58
Baseline Hb, g/dL 15.2 (1.2) 14.4 (1.2) <0.0001
Baseline serum creatinine, mg/dL, mean (SD) 0.831 (0.15) 0.823 (0.16) 0.49
Estimated creatinine clearance, mL/min, mean (SD) 124.9 (33.7) 116.4 (38.8) 0.002
Baseline RBV dose, mg/kg/day
Mean (SD) 12.1 (2.1) 11.5 (2.1) <0.0001
Median (IQR) 12.6 (2.1) 11.9 (2.8) —
RBV dose reduction due to AE during treatment, n/m (%)† 26/219 (12) 193/219 (88) <0.0001
Nadir Hb level, g/dL
Mean (SD) 11.2 (1.0) 9.1 (0.7) <.0001
Median (IQR) 10.9 (1.3) 9.2 (0.8) —
Maximum Hb decline, g/dL
Mean (SD) 4.1 (1.4) 5.3 (1.4) <.0001
Median (IQR) 4.1 (1.7) 5.3 (1.8) —
Time to anemia, days, median (IQR) NA 71 (70) —
Time to Hb nadir, days
Mean (SD) 127 (76) 137 (78) 0.08
Median (IQR) 113 (108) 114 (121)
The data include all randomized patients who underwent Hb measurement at baseline and at least once during the treatment phase up to 7 days after treatment
end date. n ¼ number of patients matching the given characteristic; m ¼ number of patients with the indicated Hb level.
Abbreviation: NA, not applicable.
*HCV subtype was ascertained via sequencing of the nonstructural 5B region.
†Includes patients with RBV dose reduction due to anemia.
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(72% [263/363]) compared with those who did not
have incident anemia (58% [212/363]). The magni-
tude of the maximum Hb decline from baseline in
patients treated with BOC/PR was also associated with
the likelihood of achieving SVR. Higher SVR rates
were observed in patients who experienced a maximum
Hb decline >3 g/dL during therapy compared
with those with a maximum decline of <3 g/dL
(Table 3).
Management of Anemia and Virologic Response.
Among patients who did not develop anemia (defined
as Hb <10 g/dL) during treatment with BOC/PR
(n ¼ 363), RBV dose reduction due to anemia as
defined by the study investigator as an AE occurred in















Week 4 undetectable, n (%) 22 (6) 17 (5) 8 (6) 0 8 (6) 1 (2)
Week 8 undetectable, n (%) 191 (53) 221 (61) 84 (61) 20 (69) 88 (61) 29 (56)
Week 12 undetectable, n (%) 238 (66) 288 (79) 110 (80) 27 (93) 114 (79) 37 (71)
Week 24 undetectable, n (%) 233 (64) 285 (79) 102 (74) 25 (86) 116 (80) 42 (81)
EOT response, n (%) 245 (67) 293 (81) 113 (82) 24 (83) 115 (79) 41 (79)
SVR, n (%) 212 (58) 263 (72) 102 (74) 21 (72) 102 (70) 38 (73)
Relapse, n/m (%) 23/245 (9) 25/293 (9) 8/113 (7) 2/24 (8) 12/115 (10) 3/41 (7)
Discontinuation due to AE, n (%) 47 (13) 123 (34) 44 (32) 9 (31) 52 (36) 18 (35)
Treatment duration, days, median (IQR) 197 (163) 203 (141) 199 (142) 278 (141) 238 (141) 197 (142)
RBV received, mg/kg/day
Mean (SD) 12.1 (2.1) 11.5 (2.1) 12.1 (1.9) 11.6 (2.1) 10.8 (2.1) 11.7 (2.2)
Median (IQR) 12.6 (2.1) 11.9 (2.8) 12.5 (2.1) 12.0 (1.7) 11.0 (3.2) 12.2 (3.0)
Time to first RBV dose modification, n (%)a*
4 weeks 0 9 (2) NA 0 9 (6) NA
>4-8 weeks 2 (1) 53 (15) NA 3 (10) 50 (34) NA
>8-12 weeks 0 44 (12) NA 2 (7) 42 (29) NA
>12-16 weeks 0 24 (7) NA 7 (24) 17 (12) NA
>16 weeks 3 (1) 43 (12) NA 17 (59) 26 (18) NA
Mean (SD), days 118 (65) 88 (61) NA 134 (66) 79 (56) NA
Median (IQR), days 123 (125) 72 (64) NA 123 (80) 61 (44) NA
Distribution of maximum RBV dose reduction, n† (%)
200 mg 4 (1) 83 (23) NA 20 (69) 63 (43) NA
400 mg 0 44 (12) NA 3 (10) 41 (28) NA
600 mg 0 17 (5) NA 1 (3) 16 (11) NA
800 mg 0 7 (2) NA 1 (3) 6 (4) NA
1,200 mg 0 1 (<1) NA 0 1 (1) NA
RBV dose interruption, n† (%)
Any interruption 0 58 (16) NA 7 (24) 51 (35) NA
3-4 days 0 9 (2) NA 1 (3) 8 (6) NA
5-7 days 0 9 (2) NA 1 (3) 8 (6) NA
8-14 days 0 19 (5) NA 3 (10) 16 (11) NA
15-28 days 0 9 (2) NA 1 (3) 8 (6) NA
>28 days 0 12 (3) NA 1 (3) 11 (8) NA
Percent intended BOV doses delivered‡
Mean (SD) 71.6 (31.8) 77.4 (27.9) 78.5 (28.7) 81.7 (22.7) 75.5 (27.5) 77.4 (30)
Median (IQR) 88.7 (52) 91.7 (39) 95.7 (39) 90.9 (20) 87.4 (43) 94 (30)
Percentage of intended RBV doses delivered§
Mean (SD) 67.3 (32.6) 71.3 (26) 75.5 (27.0) 73.6 (20.5) 66.6 (24.2) 72.3 (29.1)
Median (IQR) 81.1 (59.2) 78.7 (43) 88.7 (43) 81.5 (36) 73.7 (37) 82.9 (46)
Percentage of intended PegIFN doses delivered§
Mean (SD) 68.4 (32.1) 76.2 (26.9) 76.8 (27.4) 77.7 (22.1) 76.1 (26.0) 74.3 (30.9)
Median (IQR) 81.3 (59) 89.6 (45.8) 92.9 (46) 83.3 (30) 86.0 (44) 87.5 (44)
Abbreviation: NA, not applicable.
*One patient who received both RBV dose reduction and EPO had missing data for time of first RBV dose reduction. n ¼ number of patients administered the
given dose; m ¼ number of patients with the indicated Hb level.
†Only dose reductions/dose interruptions of at least 7 days were included.
‡Percentage of intended BOC doses delivered was calculated as follows: total dose of BOC received divided by the expected total based on actual treatment
duration. BOC dosing data was collected from patient e-diaries and drug dispensed/returned at the study site. (Excludes 77 patients with missing e-diary data.)
§Percentage of intended RBV and PegIFN doses delivered was calculated as follows: total dose received divided by the expected total dose.
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1% (5/363), EPO was used in 10% (36/363), and the
median daily RBV dose received during therapy was
12.6 mg/kg (interquartile range [IQR] of 2.1). For the
36 patients who were prescribed EPO in the absence
of protocol-defined anemia, the mean Hb level was
10.7 g/dL and the mean Hb decline from baseline was
4.5 g/dL. For the five patients who underwent RBV
dose reduction due to anemia as defined by the study
investigator as an AE, the median time to the first
RBV dose reduction was 123 days (Table 2) and the
maximum reduction was 200 mg/day. An additional
21 patients underwent an RBV dose reduction due to
other AEs, such as flu-like symptoms and rash (Table
1). Among the nonanemic patients, discontinuation of
all treatment due to an AE occurred in 13% of
patients (47/363).
For patients who developed anemia during treat-
ment with BOC/PR (n ¼ 363), anemia was managed
by the site investigators as follows: EPO without RBV
dose reduction, 38% (n ¼ 137); RBV dose reduction
without EPO, 8% (n ¼ 29); both EPO with RBV
dose reduction, 40% (n ¼ 145); and neither RBV
dose reduction nor EPO, 14% (n ¼ 52). Among ane-
mic patients, EPO was prescribed in 78% (n ¼ 282)
and the RBV dose was reduced in 48% (n ¼ 174).
Among those patients who had their RBV dose
reduced, the overall median daily RBV dose received
during treatment was 11.3 mg/kg (IQR of 3.0) which
was lower than the median daily RBV dose received
by patients who did not undergo RBV dose reduction
(12.4 mg/kg, IQR of 2.5). For patients who had their
RBV dose reduced for more than 7 days, the majority
had a maximum dose reduction of 200 mg (55%, n ¼
83) and 16% (n ¼ 25) had a maximum dose reduc-
tion of 600 mg. Among anemic patients, discontinu-
ation of all therapy due to an AE occurred in 34%
(123/363) of patients. Thirteen patients in the BOC/
PR arm discontinued all therapy due to an investigator
assessment of anemia as an AE.
The SVR rate was similar (70%-74%) for anemic
patients regardless of the approach used to manage the
anemia. Overall, patients with incident anemia were
more likely to achieve virologic response than those
who did not develop anemia, including those who
underwent RBV dose reduction. The EOT, SVR and
relapse according to the anemia management strategy
are shown in Table 2. The observed pattern of SVR
was consistent with that observed in the overall popu-
lation for smaller subgroups of patients including Afri-
can Americans (Supporting Table 3). Time to initial
RBV dose reduction was correlated with SVR. Among
the 145 patients who received both RBV dose reduc-
tion and EPO, SVR rates were 44% (4/9), 62% (31/
50), 76% (32/42), 71% (12/17), and 85% (22/26)
when the time to first RBV dose reduction was 4
weeks, >4-8 weeks, >8-12 weeks, >12-16 weeks, and
>16 weeks.
Anemia, EPO Use, and Safety. Of those who used
EPO, most patients with anemia initiated therapy
within the first 4-12 weeks of treatment and continued
to use EPO for the duration of therapy (Table 4). Of
note, the median duration of EPO use was substan-
tially shorter in the BOC/RGT arm than in the BOC/
PR48 arm (BOC/RGT, 85 days; BOC/PR48, 149
days). The incidence of treatment discontinuation due
to an AE, serious/life-threatening AEs and death was
similar in patients who were treated with EPO and
those who did not receive EPO (Table 4). In particu-
lar, no difference was observed in the frequency of car-
diovascular and/or thromboembolic events in patients
who did and did not use EPO. One case of pure red
blood cell aplasia (PRCA) occurred in a 56-year-old
Caucasian woman who was treated with BOC/PR and
received high-dose EPO (40,000 units TIW) for treat-
ment-emergent anemia (Hb nadir, 9.0 g/dL). After
approximately 36 weeks of BOC/PR therapy and 32
weeks of EPO, the patient developed new-onset pancy-
topenia; the diagnosis of PRCA was made based on
the presence of anti-EPO antibodies, and a bone mar-
row biopsy was consistent with the disease. The
patient had complete resolution of PRCA following
treatment with rituximab, intravenous immunoglobu-
lin, and methylprednisilone.
Discussion
Based on clinical trials demonstrating greater effi-
cacy, treatment with the HCV NS3/4A PIs boceprevir
and telaprevir in combination with PegIFN/RBV has
emerged as the standard of care for persons infected
with HCV genotype 1 who have never been treated




BOC Arms Combined, n ¼ 734
EOT, n/m (%) SVR, n/m (%)
 1 3/17 (17.6) 3/17 (17.6)
>1-2 2/21 (9.5) 1/21 (4.8)
>2-3 32/48 (66.6) 26/48 (54.2)
>3-4 116/160 (72.5) 103/160 (64.4)
>4-5 138/189 (73.0) 119/189 (63.0)
>5 247/299 (82.6) 223/299 (74.6)
The analysis includes eight patients with missing data. n ¼ number of
patients with EOT or SVR; m ¼ number of patients with the indicated Hb level.
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previously.15,16,20,21 Not unexpectedly, the HCV PI-
based treatment has been associated with a greater
incidence of AEs that may limit their tolerability; in
particular, incident anemia was more common in
patients treated with HCV PIs plus PegIFN/RBV
compared with PegIFN/RBV alone.15,16,20,21 Indeed,
in the clinical trials of BOC in combination with
PegIFN/RBV, anemia was identified as one of the
most common and clinically important adverse
effects.15,16 As such, our findings related to the inci-
dence of anemia and the impact of its management
with RBV dose reduction and/or adjuvant EPO have
important implications for the use of this regimen in
clinical practice.
The addition of BOC to PegIFN/RBV was associ-
ated with greater decline in the Hb level above that
observed with PegIFN/RBV combination therapy,
leading to incident anemia in 50% of patients
receiving triple therapy compared with 31% of those
treated with PegIFN/RBV alone. While the baseline
Hb level was predictive of subsequent anemia, the
magnitude of decline in Hb level at the end of the PR
lead-in phase and after 2 weeks of BOC had only
modest ability to predict which patients would remain
free of anemia. Thus, close monitoring of Hb levels
during BOC/PR therapy is needed to identify anemia
patients. Importantly, among patients in the BOC/PR
arm, the SVR rate was higher in patients who devel-
oped anemia (72%) compared with those who did not
(58%). This relationship was similar to that observed
in the patients in the PR48 arm of this study (data
not shown) and in previous studies. In two large clini-
cal trials of PegIFN/RBV, the IDEAL study (n ¼
3070) and the CHARIOT study (n ¼ 871), HCV ge-
notype 1, treatment-naı¨ve patients who developed ane-
mia, defined as an Hb level <10 g/dL during treat-
ment, were more likely to achieve SVR than those
who did not develop anemia. In both studies, anemic
patients achieved higher SVR rates than nonanemic
patients despite the receipt of less RBV due to fre-
quent RBV dose reduction up to 50% in many
patients (600 mg/day). Because the decline in Hb level
in patients treated with PegIFN/RBV is strongly corre-
lated with plasma RBV concentration, these analyses
led to the hypothesis that the higher SVR rate
observed among anemic patients may be due to higher
RBV exposure in these patients compared with nona-
nemic patients despite lower ingested RBV doses.
The observation of higher SVR rates among anemic
patients treated with BOC in combination with
PegIFN/RBV, compared with nonanemic patients, may
also reflect differences in exposure to RBV and, per-
haps, BOC. In an analysis of the relationship of meas-
ured plasma concentrations of both BOC and RBV
(steady-state AUCt) performed by pharmacologists at
the US Food and Drug Administration (FDA), there
was a significant relationship between incident anemia
and the RBV AUCt among patients treated with BOC
in combination with PegIFN/RBV (n ¼ 113, P <
0.0001) and those treated with PegIFN/RBV alone (n
¼ 51, P ¼ 0.001).22 In the same analysis, there was
also a trend toward increasing incidence of anemia and
higher BOC AUCt; however, this relationship did not
reach statistical significance. As such, in the summary
Table 4. Safety and Tolerability According to EPO Use
BOC/RGT (n ¼ 368) BOC/PR48 (n ¼ 366)
EPO (n ¼159) No EPO (n ¼ 209) EPO (n ¼ 159) No EPO (n ¼ 207)
Duration of EPO use, n (%)
4 weeks 33 (21) NA 13 (8) NA
>4-12 weeks 46 (29) NA 30 (19) NA
>12-24 weeks 63 (40) NA 44 (28) NA
>24-36 weeks 9 (6) NA 39 (25) NA
>36 weeks 8 (5) NA 33 (21) NA
Mean (SD) 93.5 (70.6) NA 156.4 (90.7) NA
Median 85 NA 149 NA
Minimum-Maximum 1-294 NA 1-305 NA
Serious AE, n (%) 21 (13) 21 (10) 19 (12) 26 (13)
Death, n (%) 0 1 (<1) 0 1 (<1)
Life-threatening AE, n (%) 1 (1) 4 (2) 3 (2) 1 (<1)
Study drug discontinuation (any drug) due to AE, n (%) 18 (11) 27 (13) 30 (19) 30 (14)
Clinically relevant AE, n (%)
Fatigue 97 (61) 99 (47) 109 (69) 100 (48)
Dyspnea 38 (24) 30 (14) 41 (26) 43 (21)
Cardiovascular and thromboembolic AE 21 (13) 22 (11) 22 (14) 25 (12)
Malignancy/malignancy-related condition 1 (1) 1 (<1) 1 (1) 1 (<1)
Abbreviation: NA, not applicable.
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of these studies of BOC and RBV concentration and
incident anemia, researchers at the FDA concluded
that these data derived from the BOC registration tri-
als support the hypothesis that the higher SVR rates
observed in patients with anemia compared with those
without anemia are due to higher RBV exposure, and
that RBV dose reduction may be an appropriate strat-
egy to management anemia with triple therapy.22
Based on this FDA analysis and other data, the US
prescribing information for BOC in combination with
PegIFN/RBV recommends that anemia be managed
with RBV dose reduction and/or discontinuation, as
has been the standard practice with PegIFN/RBV
treatment regimens.
In this study, approximately half (48%) of the
patients who developed anemia in the BOC/PR arms
underwent RBV dose reduction and, as expected, had
a lower median daily dose of RBV ingested during
therapy (11.3 mg/kg/day) compared with patients who
did not develop anemia (12.6 mg/kg/day) and those
who developed anemia but were not managed with
RBV dose reduction (12.4 mg/kg/day). Despite these
differences in ingested RBV over the course of therapy,
SVR rates were higher in anemic patients who did not
reduce their RBV dose (74%) and anemic patients
who reduced their RBV dose (71%) compared with
those who did not develop anemia (58%). These
observations suggest that following RBV dose reduc-
tion for anemia, the dose does not need to be titrated
to pre-anemia levels. Further, these data support the
hypothesis that the physiologic effect of RBV, hemo-
lytic anemia, is a better reflection of RBV exposure
than the ingested dose over the course of therapy. As
such, these data provide reassurance to clinicians that
RBV dose reduction in 200-mg increments for the
management of anemia during treatment with BOC/
PR does not substantially impair the likelihood of
SVR in such treatment-naı¨ve patients. Further research
is needed to assess this approach in other patient pop-
ulations such as those with prior treatment failure or
cirrhosis.
While RBV dose reduction represents the standard
approach to anemia during HCV treatment, the use of
ESA such as epoetin alfa to reverse anemia is more
controversial. In this study of HCV treatment-naı¨ve
patients, 43% of all patients receiving BOC/PR and
78% of those who became anemic on this regimen
were treated with adjuvant EPO and the median dura-
tion of EPO use was substantially shorter in the BOC/
RGT arm than in the BOC/PR48 arm. However, in
this study, the rate of EPO use among patients treated
with PegIFN/RBV alone was also high, 24% of all
treated patients.15 In contrast, in the large, US phase
3b IDEAL study of PegINF/RBV therapy; the fre-
quency rate of EPO use was lower at 16.3% of
patients. In addition, approximately 38% of patients
received EPO without a RBV dose reduction, though
current guidelines recommend RBV dose reduction
prior to the addition of EPO. The frequent use of
EPO may be due to an important difference in the
provision of the drug in the two studies. In the
IDEAL study, EPO was not provided by the sponsor
and was typically obtained through third party health
insurance.23 In contrast, in the current study, EPO was
provided directly by the sponsor at no cost to the
patient. Thus, the ease with which EPO could be
accessed for patients and the placebo-controlled nature
of this study may have influenced the frequency of its
prescription for the management of anemia. While in
this study, anemic patients who received EPO were
more likely to achieve SVR than those without anemia
and the incidence of adverse events was similar in
patients treated or not treated with EPO, the true
impact of EPO on the efficacy and safety of BOC in
combination with PegIFN/RBV is difficult to interpret
because most anemic patients took EPO and no appa-
rent difference was detected compared with those ane-
mic patients who did not receive EPO.
In an earlier randomized, placebo controlled trial,
the use of ESAs for the management of PegIFN/RBV
induced anemia has been associated with the partial re-
versal of treatment-related Hb decline, the mainte-
nance of the prescribed RBV dose, and the improve-
ment in the quality of life compared to management
of anemia with RBV dose reduction alone.11 In addi-
tion, in the retrospective analysis of the IDEAL study,
patients who rapidly developed anemia (within 8
weeks of starting PegIFN/RBV) had higher SVR rates
if they received ESAs, largely attributable to lower rates
of treatment discontinuation in early anemic patients
who received ESAs compared with those who did not
get ESAs. There was no apparent benefit of ESAs
observed in those who developed anemia after treat-
ment week 8. These data suggest that the primary role
of ESAs may be to prevent treatment discontinuation
in patients with severe symptoms attributed to anemia.
However, the role of ESAs in the treatment of HCV
with PegIFN/RBV-based therapy has remained contro-
versial due to its high cost and the potential for addi-
tional AEs. In other patient populations such as
patients with cancer and end-stage renal disease, ESAs
have been linked to increased risk of serious cardiovas-
cular events, tumor progression, thrombosis, and
death. In addition, PRCA due to neutralizing
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antibodies to native EPO has been reported in patients
treated with ESA including HCV-infected patients
treated with PegIFN/RBV. Indeed, in this study, one
patient developed PRCA during therapy with BOC/
PR and EPO. Taken together with the finding that
RBV dose reduction was not associated with decreased
likelihood of SVR, these data support the recommen-
dation that anemia during therapy with BOC/PR
should be managed primarily with RBV dose
reduction, and the role of EPO should be limited to
situations in which this strategy is not effective. Results
from a randomized controlled trial of the management
of anemia with RBV dose reduction alone or the
use of ESAs as first line management is expected to
provide more definitive guidance on the use of
EPO in this setting (ClinicalTrials.gov Identifier:
NCT01023035).
In conclusion, the addition of BOC to PegIFN/
RBV therapy is associated with greater risk of anemia
compared with PegIFN/RBV alone. Approximately
half of the HCV genotype 1–infected patients treated
with BOC/PR developed anemia, which was managed
with RBV dose reduction, the prescription of EPO, or
both interventions. However, the SVR rate was higher
(70%-74%) in patents with incident anemia compared
with those without anemia irrespective of the anemia
management strategy. Additional studies are underway
to further evaluate these strategies to manage treatment
emergent anemia; until such data is available, RBV
dose reduction should remain the primary approach to
anemia management during BOC/PR therapy for
treatment-naı¨ve patients.
Acknowledgment: The authors thank all the
patients, health care providers, and investigators
involved with the study. We also thank Becky Liou,
Fanxia Meng, Jianmin Long, Michael Salman, and Pe-
ter Savino for statistical and programming support.
Appendix
The investigators of The SPRINT2 Trial are: L. Colombato, J.
Curciarello, M. Silva, H. Tanno, R. Terg (Argentina); M. Adler, P.
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lich, J. Galati, G. Galler, R. Ghalib, A. Gibas, E. Godofsky, F.
Gordon, S. Gordon, J. Gross, S. Harrison, J. Herrera, S. Herrine,
K-Q. Hu, J. Imperial, I. Jacobson, D. Jones, A. Kilby, J. King, A.
Koch, K. Kowdley, E. Krawitt, P. Kwo, L. Lambiase, E. Lawitz, W.
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Schiff, T. Sepe, K. Sherman, M. Shiffman, M. Sjogren, R. Sjogren,
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The study pathologist was Zachary Goodman.
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